Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 24;10(11):869.
doi: 10.3390/diagnostics10110869.

Early Diagnosis of Pancreatic Cancer: The Key for Survival

Gina Gheorghe  1   2 , Simona Bungau  3 , Madalina Ilie  1   4 , Tapan Behl  5 , Cosmin Mihai Vesa  6 , Ciprian Brisc  7 , Nicolae Bacalbasa  8   9 , Vladiana Turi  10 , Raluca Simona Costache  1   11 , Camelia Cristina Diaconu  1   2
Affiliations
Review

Early Diagnosis of Pancreatic Cancer: The Key for Survival

Gina Gheorghe et al. Diagnostics (Basel). .

Abstract

Pancreatic cancer (PC) is one of the most aggressive forms of cancer. Negative prognosis is mainly due to the late diagnosis in advanced stages, when the disease is already therapeutically overcome. Studies in recent years have focused on identifying biomarkers that could play a role in early diagnosis, leading to the improvement of morbidity and mortality. Currently, the only biomarker widely used in the diagnosis of PC is carbohydrate antigen 19-9 (CA19.9), which has, however, more of a prognostic role in the follow-up of postoperative recurrence than a diagnostic role. Other biomarkers, recently identified as the methylation status of ADAMTS1 (A disintegrin and metalloproteinase with thrombospondin motifs 1) and BNC1 (zinc finger protein basonuclin-1) in cell-free deoxyribonucleic acid (DNA), may play a role in the early detection of PC. This review focuses on the diagnosis of PC in its early stages.

Keywords: biomarkers; carbohydrate antigen 19-9 (CA19.9); early diagnosis; pancreatic cancer; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Importance of the early recognition of risk factors and/or signs and symptoms as a starting point of investigation in pancreatic cancer (PC) diagnosis.
See this image and copyright information in PMC

References

    1. Kim V.M., Ahuja N. Early detection of pancreatic cancer. Chin. J. Cancer Res. 2015;27:321–331. doi: 10.3978/j.issn.1000-9604.2015.07.03. - DOI - PMC - PubMed
    1. Zhong Y., Naito Y., Cope L., Naranjo-Suarez S., Saunders T., Hong S.M., Goggins M.G., Herman J.M., Wolfgang C.L., Iacobuzio-Donahue C.A. Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clin. Cancer Res. 2014;20:6200–6211. doi: 10.1158/1078-0432.CCR-13-2823. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. WHO GLOBOCAN Database. [(accessed on 15 June 2020)]; Available online: https://gco.iarc.fr/today/home.
    1. Eissa M.A.L., Lerner L., Abdelfatah E., Shankar N., Canner J.K., Hasan N.M., Yaghoobi V., Huang B., Kerner Z., Takaesu F., et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin. Epigenetics. 2019;11:59. doi: 10.1186/s13148-019-0650-0. - DOI - PMC - PubMed

LinkOut - more resources